ObjectiveTo compare the short-term clinical efficacy and adverse reactions between gemcitabine combined with nedaplatin and cisplatin in the treatment of advanced lung squamous cell carcinoma.

MethodsEighty patients with advanced lung squamous cell carcinoma were randomly divided into the observation group and control group(40 cases in each group).The observation group was treated with gemcitabine combined with nedaplatin, and the control group was treated with gemcitabine combined with cisplatin for 2 cycles.The short-term efficacy, adverse reactions and influence on coagulation function were evaluated according to RECIST1.1 evaluation criteria.

ResultsThe difference of the short-term efficacy between two groups was statistically significant(P < 0.05).In terms of hematological toxicity, there was no statistical significance in the levels of white blood cell, neutrophils, hemoglobin and platelet and PLT between two groups before and after chemotherapy(P>0.05).In terms of non-hematological toxicity, there was no statistical significance in the gastrointestinal reactions(nausea, vomiting, etc.) and liver function damage between two groups before and after chemotherapy(P>0.05).After chemotherapy, the levels of D-dimer in two groups increased compared with that before chemotherapy, the increasing of which in observation group was more obvious, and the difference of which between two groups was not statistically significant(P>0.05).

ConclusionsCompared with gemcitabine combined with cisplatin, the application of gemcitabine combined with nedaplatin in patients with advanced lung squamous cell carcinoma has better short-term efficacy, less adverse reactions and influence on D-dimer.